LQDA

Liquidia Corporation
CAPPED RATING

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Liquidia Corporation (LQDA) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (A-); its weakest is Revisions (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
B+
Factor Score 3.7 / 5.0
Profitability
A-
Factor Score 3.9 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
D-
Factor Score 1.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 16.9
EV / EBITDA 17.0
Rev Growth YoY 314.6%
Gross Margin 92.7%
Price Return 3M -21.9%
Price Return 12M 109.2%
Catalyst Signal 0.00
Market Cap $5.2B
TTM Revenue $621.9M
Price / Sales 8.4
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) B+ (3.7) A- (3.9) D+ (1.7) D- (1.0) C+ (2.7)
2026-11-06 C+ (2.6) C- (2.0) A- (4.0) D (1.3) F (0.4) C- (2.0)
2026-10-30 C+ (2.7) C- (2.0) B+ (3.8) D+ (1.8) F (0.5) C (2.2)
2026-10-23 C+ (2.8) C- (2.0) A- (3.9) B (3.3) F (0.5) C (2.5)
2026-10-16 B- (2.9) C- (2.0) A- (3.9) B (3.2) F (0.0) C (2.4)
Page 1 of 8
…